Scientific & Clinical Advisory Board

Mike Palfreyman

​​Michael Palfreyman, DSc., Ph.D.

Chief Scientific Officer

Dr. Palfreyman is an internationally recognized leader in drug development with a successful scientific and business career spanning 35 years. He brings to Amorsa a distinguished track record of successful drug development and considerable expertise in CNS pharmacology, pharmacogenomics and rational drug design.

Dr. Palfreyman’s broad perspective on drug development derives from his experience as founder, President and CSO of Psychiatric Genomics; Senior Scientific Advisor to EnVivo Pharmaceuticals and Vitruvean; co-founder of NOVACE; Senior VP for Research and Development at Anadys (formerly Scriptgen); as well as senior executive and scientific leadership roles at Marion Merrell Dow (Sanofi-Aventis) and Beecham (GlaxoSmithKline). In these roles, he successfully developed and demonstrated clinical efficacy of several candidates across multiple therapeutic areas.

Dr. Palfreyman holds Ph.D. and D.Sc. degrees and is a member of the Royal Pharmaceutical Society. He continues to be an active scientific contributor with more than 150 publications and 35 issued patents.

Mihir Kamdar

Mihir Kamdar, M.D.


Dr. Kamdar graduated from Emory University School of Medicine, and completed his residency in internal medicine at Brigham and Women’s Hospital. After residency, he completed the Harvard Palliative Medicine fellowship, followed by a second fellowship in Interventional Pain at the MGH Department of Anesthesia’s Center for Pain.

Trained in both palliative care and interventional pain techniques, he currently co-directs the MGH Cancer Pain Clinic with a focus is on minimally invasive pain interventions, such as neurolytic blockade and neuraxial drug delivery, for palliative care patients with refractory cancer pain.

Maurizio Fava

Maurizio Fava, M.D.


Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology there. He completed residency training in psychiatry at Mass. General Hospital (MGH). He founded and was Director of the MGH Depression Clinical and Research Program (DCRP) from 1990 until 2014. Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, conducting research in pharmacotherapy of resistant depression, neuroimaging, genetics, neurophysiology, neuroendocrinology, novel pharmacotherapies, alternative medicine, and psychotherapy. Dr. Fava successfully obtained funding for his program, as principal or co-principal investigator, from the NIH and industry for a total of more than $60,000,000 in the past 23 years. Since 2007, he has been Director of the MGH Clinical Trials Network and Institute, an academic CRO specialized in multicenter trials and in the use of innovative research methodologies. In 2014, Dr. Fava was selected as Director of MGH’s Clinical Research Program (CRP).

Dr. Fava authored or co-authored more than 600 original articles in medical journals with international circulation. He has also edited eight books, and published more than 50 chapters and 500 abstracts. Dr. Fava is a well-known speaker, having given more than 350 presentations at national and international meetings. He is currently Director, MGH’s CRP, Executive Vice Chair for the MGH Dept. of Psychiatry, Executive Director, CTNI, and Slater Family Professor of Psychiatry at Harvard Medical School.​​

Robert Lenox

Robert Lenox, M.D.


Dr. Lenox is President of RHL Consulting, LLC, providing CNS drug discovery and development consultation to academia, biotech and venture capital firms. Dr. Lenox is also Professor of Pharmacology and Clinical Neurosciences in the College of Osteopathic Medicine at the University of New England and is scientific advisor to the NIH funded Interdisciplinary Center of Excellence for the study of Pain and Sensory Function. Until recently he served as Vice Preside and Worldwide Head of CNS Drug Discovery at Sanofi Pharmaceuticals.

He holds a Bachelor of Science degree in Biochemistry from MIT, a medical degree from the University of Vermont College of Medicine and a Masters of Arts (Honors) from the University of Pennsylvania.

Lt Col (Ret) John Gandy, M.D.


Dr. John Gandy is a Board Certified Emergency Medicine Physician who served as both an enlisted medic and physician in his 28-year military career. He retired from the United States Air Force in 2008 and during that time he was involved with numerous worldwide deployments supporting military Special Operations Forces.

Dr. Gandy has received a presidential appointment to the Defense Health Board advising the Secretary of Defense on all medical issues including best practices, treatment protocols, medications, vaccines, and battlefield medicine. He is currently serving on the Technical Combat Casualty Care committee board advising on all issues of casualty care from point of injury to tertiary care. Dr. Gandy also sits on the editorial board for the Journal of Special Operations Medicine.

He attended medical school at USUHS, Bethesda, MD and residency at Wilford Hall/Brooke Army Medical Center in San Antonio, Texas.